Guillain-Barre Syndrome - Pipeline Review, H1 2018

  • ID: 4515987
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Annexon Inc
  • Complement Pharma BV
  • CuraVac Inc
  • Hansa Medical AB
  • Vitality Biopharma Inc
  • MORE
Guillain-Barre Syndrome - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2018, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Annexon Inc
  • Complement Pharma BV
  • CuraVac Inc
  • Hansa Medical AB
  • Vitality Biopharma Inc
  • MORE
Introduction

Report Coverage

Guillain-Barre Syndrome - Overview

Guillain-Barre Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Guillain-Barre Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Guillain-Barre Syndrome - Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Annexon Inc

Complement Pharma BV

CuraVac Inc

Hansa Medical AB

Vitality Biopharma Inc

Guillain-Barre Syndrome - Drug Profiles

ANX-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imlifidase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Guillain-Barre Syndrome - Dormant Projects

Guillain-Barre Syndrome - Product Development Milestones

Featured News & Press Releases

Feb 16, 2018 : Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barre syndrome

Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome

May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barré Syndrome

May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barré Syndrome

Jan 29, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Guillain-Barre Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Guillain-Barre Syndrome - Pipeline by Akari Therapeutics Plc, H1 2018

Guillain-Barre Syndrome - Pipeline by Annexon Inc, H1 2018

Guillain-Barre Syndrome - Pipeline by Complement Pharma BV, H1 2018

Guillain-Barre Syndrome - Pipeline by CuraVac Inc, H1 2018

Guillain-Barre Syndrome - Pipeline by Hansa Medical AB, H1 2018

Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H1 2018

Guillain-Barre Syndrome - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Guillain-Barre Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akari Therapeutics Plc
  • Annexon Inc
  • Complement Pharma BV
  • CuraVac Inc
  • Hansa Medical AB
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll